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Abstract 
Objective: Objective of the present analytical research work was to develop and validate Spectrophotometric 
method and Reverse Phase High Performance Liquid Chromatographic method (RP-HPLC Method) for the 
Eszopiclone bulk and tablets dosage form. 
Methods: A spectrophotometric method and a RP-HPLC method have been developed and validated for 
estimation of ESZ in pharmaceutical oral dosage form. 
Method A (RP-HPLC Method): The RP-HPLC Method for Eszopiclone was developed using Shimadzu 
HPLC, LC-10, temperature maintained 250C, phenorex Gemini C18 (250 mm × 4.60 mm × 5µm), as stationary 
particle, isocratic mode. MeOH: Water (80:20v/v) as mobile phase. Mobile phase was maintained at a flow 
rate of 1.0 ml/min and detection was carried out at 305 nm. 
Method B (UV SPECTROMETRY Method): The stock and working standard solutions of the drugs were 
prepared in methanol. Standard solutions were scanned over the range of 400-200 nm in spectrum mode of 
spectrophotometer at medium scanning speed using UV spectrophotometer 2450, SHIMADZU. The maximum 
absorbance for Eszopiclone was found at 305 nm. Both the methods were validated in accordance with ICH 
guidelines 
Results: Eszopiclone was found to be linear in the concentration range of 4 - 24 µg/ml for spectrophotometric 
method and 5-30 µg/ml for RP-HPLC method. Retention time was found to be 5.38 min for Eszopiclone. The 
amount of Eszopiclone in marketed formulation by spectrophotometric method was found to be 100.02 %, the 
amount of Eszopiclone in marketed formulation by RP-HPLC method was found to be 100.03 %. 
Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the 
methods can be successfully applied for the routine analysis of Eszopiclone. 
Keywords: Eszopiclone, RP-HPLC, UV Spectrometry, ICH Guidelines 
 
1. Introduction 
Insomnia is a sleep disorder in which there is an 
inability to fall asleep or to stay asleep as long as 
desired. Insomnia is very common and occurs in 30% 
to 50% of the general population. 10% of the 
population may suffer from chronic (long-standing) 
insomnia. Insomnia affects people of all ages 
including children, although it is more common in 
adults and its frequency increases with age.1 In 
general, women are affected more frequently than 
men. There are various symptoms of insomnia like 
difficulty falling asleep despite being tired,walking up 
frequently during the night,trouble getting back to 
sleep when awakened,difficulty with memory,relying 
on sleeping pills or alcohol to fall a sleep,walking up 
too early in the morning,daytime drowsiness, fatigue 
or irritability,difficulty concentrating during the day. 
Eszopiclone is one of the drug is available in the 
market for the treatment of insomnia.2 
Eszopiclone is Calcium chnnel blocker acts on 
benzodiazepine binding site situated on GABAA 
neurons as an agonist. Cytochrome P450 (CYP) 
isozymes CYP3A4 and CYP2E1 are involved in the 
biotransformation of Eszopiclone. γ- Amino butyric 
acid (GABA) is the most important inhibitory 
neurotransmitter in the mammalian brain and 
localizes to approximately 30% of CNS synapses. 
This inhibitory neurotransmitter is of particular 
interest because most therapeutically useful hypnotic 
drugs work by selectively affecting GABA receptors. 
A number of classes of GABA receptors including the 
GABAA, GABAB, and GABAC receptors have been 
characterized in the CNS of several species, including 
man. The distribution of GABA receptor types varies 
throughout the CNS. The GABAA receptor is the site 
of action of Eszopiclone. It modulates GABAnergic 
function through different GABAA receptor sub-
types, defined by the subunits that participate in the 
receptor assembly. Most GABAA receptors consist of 
α, β, and γ subunits which contain multiple isoforms 
or variants: α1–α6, β1–β3, and γ1–γ3.3 
Literature survey reveals that only a few analytical 
methods are reported for the estimation of  
Eszopiclone. In this study efforts were made to 
develop a simple, easy and economic UV-Visible 
Spectrophotometry and HPLC methods for the 
estimation of Eszopiclone. The developed method 
was optimized and validated as per the guidelines of 
International conference on Hormonization (ICH) and 
demonstrated excellent specificity, linearity, precision 
and accuracy for Eszopiclone. Validation is a process 
of establishing documented evidence, which provides 
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a high degree of assurance that a specific activity will 
consistently produce a desired result or product 
meeting its predetermined specifications and quality 
characteristics. Method validation is the process of 
demonstrating that analytical procedures are suitable 
for their intended use and that they support the 
identity, quality, purity, and potency of the drug 
substances and drug products.4, 5, 6 
 
2. Materials and methods 
2.1 Preliminary analysis of drug 
Eszopiclone (ESZ) is official in United States 
Pharmacopoeia (USP). It is in Authorized USP 
Pending Monograph Version 1. Hence, Preliminary 
analysis of ECZ was performed according to USP. 
2.1.1 Description 
The sample of ECZ was observed for its color and 
texture. 
2.1.2 Solubility 
The sample of ECZ was taken in test tubes and 
observed for solubility in various solvents like methyl 
chloride, diluted mineral acids water, alcohol and 
water. 
2.1.3 Water Determination 
Water content can be determined using Karl Fischer 
Titrimeter. Karl Fischer reagent is standardize with 
sodium tartrate, then it is allowed to titrate with the 
known amount of sample i.e. ESZ and then once the 
color change is observed, it will indicate the end point 
of the titration and this in turn will give the amount of 
moisture present in the sample. Moisture/water 
content can be determine using following formula, 
 
Water content = Burette reading × Karl Fisher factor× 100 
                                    Weight of Sample (mg) 
 
2.2 Chemicals and Reagents (HPLC) 
Analytically pure samples of Eszopiclone were kindly 
supplied by Sun Pharmaceuticals Ltd, Vapi, Gujarat, 
India. Zopipure (Marketed Formulation), Water 
(HPLC Grade), MeOH (HPLC 
Grade)  Themis laboratories Pvt.Ltd (Mumbai,India), 
were used for the method development. 
2.2 Instrument Used 
Electronic Weighing Balance (Tapson’s Analytical 
Balance), Ultrasonicator (Tapson’s TP-101), 
Cellulose Acetate Filter, 0.45 µm (Nylon 66), HPLC 
System (Shimadzu) 
2.3 Selection of Mobile Phase 
The selection was made on the basis of literature 
survey. After assessing the solubility of drug in 
different solvents as well on the basis of literature 
survey, Methanol and Double RO water were selected 
as a first choice. 
2.4 Selection of column (stationary phase) 
To get well resolved, symmetric peak with highest no. 
of theoretical plates, the solution of ESZ was 
analyzed using different column as a stationary phase 
like Phenyl, C18, Amino column. 
2.5 Selection of Analytical Wavelength 
To investigate the appropriate wavelength for 
determination of ESZ, the solution of the same in the 
MeOH were scanned separately by UV–Visible 
spectrophotometer in the range of 190-400 nm and 
the spectrum were recorded. 
2.6 Preparation of Mobile Phase 
Mobile Phase A: HPLC grade MeOH was degassed 
in sonicator for 15 min. 
Mobile Phase B: Double RO water 
2.7 Preparation of Standard Stock Solution 
Standard stock solution was prepared by dissolving 
10 mg of ESZ in 100 ml methanol that gives 
concentration of 100 g/ml of ESZ and labeled as 
Standard stock ESZ. 
2.8 Preparation of Calibration Curve for ESZ 
2.9 Analysis of Zopipure I (Sun Pharmaceutical 
Ltd) 
To determine the content of ESZ in conventional 
tablets (Label claim 1 mg ESZ per tablet); the twenty 
tablets were weighed, their mean weight determined 
and they were finely powered and powder equivalent 
1.0 mg ESZ was transferred into a 100 mL volumetric 
flask containing 40 mL methanol, sonicated for 30 
min and diluted to 100 mL with methanol (10 
µg/mL). The resulting solution was filtered, using 
0.22 µm filter (Millifilter, Milford, MA) and injected 
into system. The amount of ESZ was determined. The 
assay procedure was repeated for six times and 
Calculated using following equation. 
 
          Ct= Rt × Cs                               
                    Rs 
Where, Ct and Cs = Concentration of Sample and 
Standard Solution, respectively.  
Rt and Rs = Peak Area for Sample and Standard 
Solution, respectively. 
2.10 Validation of RP-HPLC Method 
2.10.1 Accuracy 
Accuracy of the method was assessed by standard 
addtition method at three different concentration 
levels i.e. 80%, 100, 120%. From sample stock 
solution ESZ (100 µg/ml), pipette out 10 ml to each 
of four different 100 ml volumetric flask and add to it 
0.0 ml, 8.0 ml, 10.0 ml and 12.0 ml of standard stock 
solution ESZ (100 µg/ml) and make up the volume 
with MeOH. The % Recoveries was calculated by 
applying regression equation. 
2.10.2 Precision 
The precision of an analytical method was studied by 
performing repeatability and intermediate precision. 
2.10.3 Repeatability 
Suitable aliquot from standard stock solution ESZ 
(100 µg/ml) 1 ml was pipetted in 10 ml volumetric 
flask and make up the volume to get final 
concentration of 10 µg/ml and analyzed six times on 
the same at optimized chromatographic conditions. 
2.10.4 Intermediate Precision 
2.10.4.1 Intra-day Precision 
Intra-day precision was determined by analyzing the 
standard solutions of ESZ (10, 15, 20 µg/ml) and at 
three different time intervals on same day. 
2.10.4.2 Inter-day Precision 
Inter-day precision was determined by analyzing the 
combined standard solutions of ESZ (10, 15, 20 
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µg/ml) on three consecutive days. The results were 
reported in terms of % RSD. 
2.10.5 Linearity and Range 
The linearity of analytical method for ESZ was 
determined by studying standard calibration curves. 
The range of analytical method was decided from the 
interval between upper and lower level of calibration 
curves by plotting the log curve. 
2.10.6 Limit of Detection and Limit of Quantitation 
Detection limit and quantitation limit were 
determined based on the standard deviation of y-
intercepts of six calibration curves and average slope 
of six calibration curves. 
 LOD = 3.3 × Standard deviation of intercept 
       Slope 
 
 LOD = 10× Standard deviation of intercept 
       Slope 
2.10.7 Robustness 
Standard stock solution of ESZ (100 µg/ml)) were 
used and analyzed at different flow rate (0.9, 1.00, 1.1 
ml/min) and at different mobile phase ratio (79:21, 
80:20, 81:21 v/v) separately. 
2.10.8 System Suitability 
Standard solution of ESZ (100 µg/ml) was prepared 
and analyzed. Chromatograms were studied for 
different parameters such as tailing factor, resolution 
and theoretical plates to see that whether they 
complies with the recommended limit or not. 
2.10.9 Specificity and Selectivity 
The analytes should have no interference from other 
extraneous components and be well resolved from 
them. Specificity is a procedure to detect 
quantitatively the analyte in presence of component 
that may be expected to be present in the sample 
matrix, while selectivity is the procedure to detect 
qualitatively the analyte in presence of components 
that may be expected to be present in the sample 
matrix. The method is quite selective. There was no 
other interfering peak around the retention time of 
ESZ; also the base line did not show any significant 
noise. 
2.10.10 Ruggedness 
Ruggedness of the method was checked by two 
different analysts keeping same experimental and 
environmental conditions. An appropriate 
concentration 10 µg/ml of ESZ was subjected to 
analysis and concentration was determined. This 
procedure was repeated six times. 
2.11 Chemicals and Reagents (UV Visible 
Spectrophotometric) 
Eszopiclone (Standard)*,Zopipure (Marketed 
Formulation) [Label claim: 1mg of ESZ mg per tablet 
],MeOH (AR Grade),Chloroform (AR Grade),0.1M 
NaOH,0.1M HCl, *Eszopiclone was provided by Sun 
pharma, Vapi, Gujarat. 
2.12 Instruments Used 
Electronic Weighing Balance (Tapson’s Analytical 
Balance), Ultrasonicator (Tapson’s TP-101) 
UV–Visible Spectrophotometer (UV 
spectrophotometer 119, Systronics, Software Version 
1) 
2.13 Selection of Solvent 
Solutions of ESZ (100 µg/ml) was prepared in 
different solvents like 0.1M HCl, 0.1M NaOH, 
methanol and Chloroform. These solutions were 
scanned in UVVisible Region (200 nm to 800 nm) 
and intensity of absorption and wavelength of 
absorption were studied. 
2.14 Preparation of Standard Stock Solution 
Standard stock solution was prepared. 
2.15 Selection of Wavelength Range 
From the stock solutions, 1.0 ml of ESZ was 
transferred to 10 ml volumetric flask and the volume 
was adjusted to the mark with MeOH to obtain 
Strength 10µg/ml. The solution was scanned in the 
UV range 200-400 nm. 
2.16 Preparation for Calibration Curve 
Calibration curve were prepared and graph was 
plotted. 
2.17 Determination of E (1%, 1 cm) and Molar 
Absorptivity 
Aliquot portions of ESZ stock standard solution were 
transferred in to five different 10 ml volumetric 
flasks; diluted with same solvent to obtain 
concentration of 16 µg/ml. The absorbance of each 
solution was measured at 305.0 nm. A (1%, 1cm) 
values of drugs were calculated using following 
formula, A (1%, 1cm) = Absorbance/Concentration 
(g/100ml) 
Molar absorptivity was determined from following 
equation. 
 
Molar absorptivity = Absorptivity × Molecular weight 
                                                        10 
2.18 Analysis of zopipure 
For analysis of commercial formulation, twenty 
tablets were weighed, average weight determined and 
crushed into fine powder. An accurately weighed 
quantity of powder equivalent to 1 mg of ESZ was 
transferred into 100 ml volumetric flask containing 30 
ml methanol (50%,v/v), shaken manually for 10 min, 
volume was adjusted to mark with same solvent and 
filtered through Whitman filter paper no. 41. The 
absorbance of sample solution was recorded at 
recorded at 305 nm. 
2.19 Validation of Spectrophotometric Method 
2.19.1 Accuracy 
Accuracy of the method was assessed by standard 
addtition method at three different concentration 
levels i.e. 80%, 100, 120%. From sample stock 
solution ESZ (100 µg/ml), pipette out 10 ml to each 
of four different 100 ml volumetric flask and add to it 
0.0 ml, 8.0 ml, 10.0 ml and 12.0 ml of standard stock 
solution ESZ (100 µg/ml) and make up the volume 
with MeOH. The % recovery was then calculated by 
using formula 
% Recovery = A – B/ C, Where, 
A = Total amount of drug estimated 
B = Amount of drug found on pre analysed basis 
C = Amount of Pure drug added 
2.19.2 Precision 
The precision of an analytical method was studied by 
performing Repeatability and Intermediate precision. 
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2.19.3 Repeatability 
Suitable aliquot from standard stock solution ESZ 
(100 µg/ml) 1 ml was pipetted in 10 ml volumetric 
flask and make up the volume to get final 
concentration of 10 µg/ml and analyzed six times on 
the same at optimized chromatographic conditions 
The standard deviation and % Relative standard 
deviation were also calculated. 
2.19.4 Intermediate precision 
2.19.4.1 Intra-day Precision 
Intra-day precision was determined by analyzing the 
12, 16, 20 µg/ml of ESZ for three times in the same 
day. 
2.19.4.2 Inter-day Precision 
Inter-day precision was determined by measuring the 
the 12, 16, 20 µg/ml of ESZ for three consecutive 
days. 
2.19.5 Linearity and Range  
The linearity of analytical method for ESZ was 
determined by studying standard calibration curves. 
The range of analytical method was decided from the 
interval between upper and lower level of calibration 
curves by plotting the log curve. 
2.19.6 Limit of Detection (LOD) and Limit of 
Quantitation (LOQ) 
Detection limit and quantitation limit were 
determined based on the standard deviation of y-
intercepts of six calibration curves and average slope 
of six calibration curves. 
 
LOD = 3.3 × Standard deviation of intercept 
        Slope 
 LOD = 10× Standard deviation of intercept 
        Slope 
2.19.7 Ruggedness 
Ruggedness of the method was checked by two 
different analysts keeping same experimental and 
environmental conditions. An appropriate 
concentration 10 µg/ml of ESZ was subjected to 
analysis and concentration was determined. This 
procedure was repeated six times.5-13 
 
3. Results and discussion 
3.1 Preliminary analysis of drug 
Preliminary analysis of Eszopiclone such as 
description, solubility, identification test and assay 
were performed according to available literature 
survey and complied with USP. A white to slightly 
fine powder was found which was complied with 
USP. Drug was soluble in methanol, methylene 
chloride and insoluble in water and alcohol. Water 
content was found 0.2%. 
3.2 High Performance liquid Chromatographic 
Method 
3.2.1. Method A: Reverse Phase HPLC method 
By the literature survey RP-HPLC method for 
estimation of Eszopiclone was reported using RP8 
column (150mm×4.6mm i.d., 3.5m particle size) 
column. Initially, RP8 column was tried to achieve 
good peak, but it was not obtained thus this prompted 
to use Phenomenex Gemini C18 column (250 mm x 
4.6.0 mm, 5 µ), thus Phenomenex Gemini C18 
column was selected. The observed for ESZ were min 
5.38 min. Thus the mobile phase containing mixture 
MeOH: Water (80:20 v/v), at a flow rate of 1 ml/min 
with UV detection at 305 nm, using Phenomenex 
Gemini C18 column (250 mm x 4.6.0 mm, 5 µ) as a 
stationary phase was finalized. This also improved the 
column efficiency and ease of separation. Table 1, 
Figure1, 2, 3  
3.2.2 Selection of Analytical Wavelength 
The standard solutions of ESZ (100 µg/ml) in mobile 
phase were scanned in the UV region of 190 - 400 nm 
and the overlain spectra were recorded. It was 
observed that ESZ drugs showed the absorbance at 
305 nm. So, the wavelength of detection used was 
305 nm. 
3.2.3 Linearity Study 
ESZ was found to be linear in the concentration range 
of 5-30 µg/ml. Table 2 and Table 3   
3.2.4 Assay of Marketed Formulation 
Amount of drugs present in the marketed formulation 
(Zopipure I, Sun Pharmaceutical Ltd.) using 
equations mentioned in the section no. 4.2.8.Amount 
of ESZ found in the range from 100.03% and SD ± 
0.70. Table 4 
3.2.5 Validation Parameters 
This method was validated in accordance to ICH 
guidelines. Percentage of recoveries of ESZ was 
found in the range from 99.90 – 100.09%. Precision 
of the method was determined by % RSD found 
among intra-day precision, inter-day precision, 
repeatability. LOD and LOQ of ESZ were found to be 
0.310 and 0.572µg/ml, respectively. For robustness 
study, the effect of change in of mobile phase, mobile 
phase ratio and flow rate (1.0 ± 0.2 ml/min) on the 
Mean peak area, % RSD and % Assay were studied. 
Standard solutions of ESZ (100 µg/ml), was prepared 
and analyzed at different mobile phase ratio (90:10, 
80:10, 50:50v/v) and at different flow rate (0.99, 1.00, 
1.1 ml/min). Percentage RSD of each peak in all 
variables was found to be less than 3 %. Table 5, 6, 7, 
8, 9, 10 
3.3 UV-Visible Spectrophotometric Methods 
3.3.1 Selection of solvent 
The spectrum of the drug in different solvents like 
0.1M HCl, 0.1M NaOH, methanol and chloroform 
were studied carefully during the development of UV-
Visible spectrophotometric method. But among all 
these spectra’s of ESZ obtained from various 
solvents, the spectrum obtained with 50%v/v 
methanol was found to be better as ESZ was stable in 
solvent, shows very distinct and clear absorbance at 
305 nm. Figure 4, 5 
3.3.2 Single Point Method 
As traditional UV spectrophotometric method 
development was found suitable for estimation of this 
drug from marketed formulation. So, estimation was 
done with the help of spectrum mode of analysis. In 
this method methanol was used as a solvent while 
ESZ absorbed at 305nm and wavelength range of 400 
nm to 200 nm was selected for the absorbance mode 
of analysis at medium scanning speed. 
3.3.3 Linearity Study 
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Standard solution having concentration range of 4, 8, 
12, 16, 20, 24 and µg/ml of ESZ was prepared. 
Absorbances of these solutions were recorded at 
305.0 nm. Calibration curve was plotted, absorbance 
vs concentration. Table 11 
3.3.4 Assay of Marketed Formulation 
Using this method, the marketed formulation 
(Zopipure I, Sun Pharmaceutical Ltd.) was analyzed. 
Sample solution containing 10 µg/ml. The amount of 
drug present in the marketed formulation was 
calculated .The mean % assay of ESZ was found to be 
100.02%. Table 12, 13, 14 
3.3.5 Validation Parameters 
Validation of the method was performed in 
accordance to ICH guidelines. Accuracy of the 
method was determined at 80%, 100% and 120% 
level by standard addition method and percentage 
recovery ESZ were found to be in the range of 99.54 
– 100.10 %. Precision of the method was determined 
by % RSD of intra-day precision, inter-day precision, 
and repeatability. It was found to be less LOD and 
LOQ of ESZ was found to be 0.429 and 1.310 µg/ml, 
respectively. Table 15,16,17,18 
 
4. Conclusion 
In the present investigation, the developed and 
validated, UV Spectrophotometric method were 
found to be simple, economical and rapid method. 
RP-HPLC was found to more precise, accurate, 
rugged and robust for determination of Esczopiclone. 
The excipients usually present in the pharmaceutical 
formulation did not interfere with determination of 
Eszopiclone. Developed method can be successfully 
used in laboratory to measure the concentration of 
API in specific dosage form. This method is also 
beneficial for the formulation and development 
department. These methods are always useful for 
analysis, purity testing and assay. The consumption of 
time and chemicals is less as compare to other tedious 
method. This is new concept for the validation of 
method development and method transfer in 
pharmaceutical companies. The results and the 
statistical parameters demonstrate that the proposed 
UV spectrophotometric and RP-HPLC method is 
simple, rapid, specific, accurate and precise. 
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Table 1 Observation and remarks of mobile phase Optimization of Chromatographic Conditions 
 
Mobile Phase Composition Inference Conclusion 
MeOH : Water (10 : 90 v/v)  Rt of Esz greater  than 10  Mobile phase was  not satisfactory
MeOH : Water (20 : 80v/v) Rt of Esz was around 9.10 Mobile phase was not satisfactory
MeOH : Water (50 : 50v/v) Rt of Esz was  around 7 Mobile phase was not satisfactory
MeOH : Water (90 : 10 v/v)  Asymmetry was less. Mobile phase was  not satisfactory
MeOH : Water (80 : 20 v/v Rt of Esz was  around 5.38 , Assymmetry 
was good 
Mobile phase was  suitable 
(optimized) 
 
Table 2 Results of Calibration Curve of ESZ 
 
S.No Concentration of ESZ [µg/mL] Area Mean % RSD 
1 5 142161.6 0.80 
2 10 295647.2 0.60 
3 15 423567.2 0.30 
4 20 571901.3 0.85 
5 25 702345.7 0.79 
6 30 842356.1 0.32 
 
Table 3 Linear Regression Analysis of Calibration Curves for ESZ 
 
Linearity Range (µg/ml) 5-30 
Slope 27825
Intercept 9389.6 
Correlation Coefficient (r2) 0.9995 
LOD (µg/ml) 0.310 
LOQ (µg/ml) 0.572 
 
Table 4 Assay Results of Zopipure RP-HPLC Method 
 
Label Claim 
[mg] 
Amount found 
[mg]
[%] of Assay 
10 10.02 100.02 
10 10.08 100.08 
10 10.10 101.10 
10 9.97 99.70 
10 9.93 99.31 
10 10.01 100.01
  
Table 5  Results of Accuracy for RP-HPLC Method 
 
Initial Amount 
[ µg/mL] 
Amount added 
[µg/mL] 
Amount recovered 
± S.D [µg/mL, n=3] 
% Recovery 
 
% RSD 
 
10 0 9.99 ± 0.06 99.90 0.52 
10 8 17.97 ± 0.06 99.83 0.82 
10 10 19.96 ± 0.05 99.80 0.65 
10 12 22.02 ± 0.05 100.09 0.40 
 
Table 6 Results of intra-day precision and inter-day precision 
 
Concentration [µg/ml] Intra-day Precision Inter-day Precision 
 Mean  
% RSD 
 
Mean 
[n= 3] 
% RSD  
[n= 3] 
10 10.13 1.85 10.12 0.43 
15 14.97 1.37 14.90 1.51 
20 19.73 1.48 19.73 1.10 
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Table 7   Results of Repeatability Study for ESZ 
 
Mean 279540.2 
S.D 376.62 
% RSD 0.65 
 
Table 8  Result of Robustness Study: Variation in Mobile phase Ratio 
 
Percentage Methanol in 
Mobile phase (v/v) 
RT K’ T 
         81 6.05 1.20 1.47 
         80 5.38 0.90 1.40            
        79 4.01 0.73 1.45 
Mean ± SD 5.14 ± 0.60 0.94 ± 0.20 1.44 ± 0.04 
 
Table  9  Results of Ruggedness 
 
Analysts 
[n=3] 
Amount found of ESZ [%] 
 
%RSD 
 
       I 100.04 0.34 
       II 100.05 0.40 
                                                          
Table 10 Results of System Suitability Parameters 
 
Analyte Retention time (min) Tailing Factor Theoaretical plates (N) Capacity Factor         
ESZ 5.3 1.40 4122                                 0.92 
 
Table 11 Results of Calibration Curve of ESZ 
 
S. No Concentration of ESZ 
[µg/mL] 
Absorbance Mean 
 
% RSD 
1 4 0.143±0.0011 0.68 
2 8 0.285±0.0011 0.34 
3 12 0.416±0.0009 0.20
4 16 0.554±0.0011 0.17
5 20 0.680±0.0012 0.15 
6 24 0.805±0.0011 0.12 
 
Table 12 Linear Regression Analysis of Calibration Curves for ESZ 
 
Parameters ESZ 
Linearity Range (µg/ml) 4-24 
Slope 0.0331 
Intercept 0.172 
Correlation Coefficient (r2) 0.9995 
LOD (µg/ml) 0.429 
LOQ (µg/ml) 1.310 
 
Table 13  Analysis of ESZ in bulk sample 
 
Amount Taken 
(µg/ml) 
Amount Found  
(µg/ml) 
Amount Found ± SD 
(%, n = 5) 
% R.S.D. 
 
   10 9.98 99.8±0.26 0.26 
 
Table 14  Analysis of Zopipure –I (ESZ tablets) 
 
Sample Label claimed %Label claim ± SD %RSD 
   1 10 100.02±0.47 0.47 
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Table 15  Accuracy of ESZ 
 
Initial Amount 
[µg/ml] 
Amount added 
[µg/ml] 
Amount Recovered % Recovered 
[µg/ml] 
% 
R.S.D 
10 8 17.94 99.54 0.18 
10 10 20.00 100.02 0.23 
10 12 12.05 100.10 0.13 
 
Table 16 Results of intra-day precision and inter-day precision 
 
Concentration 
[µg/ml] 
Intra-day Precision Inter-day Precision 
 Average potency % RSD [n= 3] Average potency RSD % [n= 3] 
10 99.70% 0.21 99.33% 0.39 
15 99.85% 0.40 99.69% 0.47 
20 99.60% 0.46 99.90% 0.55 
                                          
Table 17 Results of Repeatability Study for ESZ 
 
Mean 279540.2 
S.D 376.62 
% RSD 0.44 
 
Table 18   Results of Ruggedness 
 
Analysts    [n=3] Amount found of ESZ [%] %RSD 
       I 100.04 ± 0.42 0.42 
       II 100.05 ± 0.23 0.23 
                                                          
Figure 1 HPLC chromatogram of Blank (diluents) MeOH: Water (80:20, v/v) 
 
Figure 2 HPLC chromatogram of ESZ standard (100 µg/ml) mobile phase at flow rate of 1 ml/min, at 
305nm, 
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Figure 3 HPLC chromatogram of sample ESZ (10 µg/ml) in the optimized mobile phase at flow rate of 1 
ml/min, at 305nm, C18 colum 
 
 
Figure 4  Spectrum of eszopiclone in 50% v/v methanol 
 
 
 
Figure 5  Overlain spectra of ESZ (4 - 24 µg/ml) in methanol 
 
 
 
 
